Skip to main content
Alpha Cognition Inc. logo

Alpha Cognition Inc. — Investor Relations & Filings

Ticker · ACOG ISIN · CA02074J2048 LEI · 254900J4A8UTBGYKPA90 US Manufacturing
Filings indexed 174 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country CA Canada
Listing US ACOG

About Alpha Cognition Inc.

https://www.alphacognition.com/

Alpha Cognition Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing treatments for patients with neurodegenerative diseases. The company's primary focus is on conditions such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Its lead product, ZUNVEYL® (benzgalantamine), is a novel cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type. ZUNVEYL is designed with an optimized drug delivery system to improve patient outcomes and address underserved needs in neurological health.

Recent filings

Filing Released Lang Actions
QUARTERLY REPORT
Interim / Quarterly Report
2026-05-14 English
DEF 14A - Alpha Cognition Inc. (0001655923) (Filer)
Proxy Solicitation & Information Statement
2026-04-30 English
8-K - Alpha Cognition Inc. (0001655923) (Filer)
Regulatory Filings
2026-04-14 English
4 - Alpha Cognition Inc. (0001655923) (Issuer)
Director's Dealing
2026-03-26 English
4 - Alpha Cognition Inc. (0001655923) (Issuer)
Director's Dealing
2026-03-20 English
4 - Alpha Cognition Inc. (0001655923) (Issuer)
Director's Dealing
2026-03-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.